Salarius Pharmaceuticals, Inc. regains compliance with Nasdaq listing requirements, paving the way for its planned merger with Decoy Therapeutics. The merger will create a new company named Decoy Therapeutics focused on peptide conjugate therapeutics for respiratory infectious diseases and GI oncology. Decoy plans to advance a pan-coronavirus antiviral and other programs in the next 12 months. Salarius’ seclidemstat may also be evaluated for myelodysplastic syndrome and chronic myelomonocytic leukemia. The combined company will be led by executives from Decoy and Salarius. For more information, visit www.DecoyTx.com and www.salariuspharma.com.

Read more at GlobeNewswire: Salarius Pharmaceuticals Regains Compliance with All Nasdaq